Evidence map›Paper›PMID 27348615›Full record

ArticlePloS one2016

In Vitro Endothelialization Test of Biomaterials Using Immortalized Endothelial Cells.

Ken Kono, Hitomi Hiruma, Shingo Kobayashi, Yoji Sato, Masaru Tanaka, Rumi Sawada, Shingo Niimi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ken KonoDivision of Cell-Based Therapeutic Products, National Institute of Health Sciences, Tokyo, Japan.
Hitomi HirumaDivision of Medical Devices, National Institute of Health Sciences, Tokyo, Japan.
Shingo KobayashiSoft Materials Chemistry, Institute for Materials Chemistry and Engineering, Kyushu University, Fukuoka, Japan.
Yoji SatoDivision of Cell-Based Therapeutic Products, National Institute of Health Sciences, Tokyo, Japan.
Masaru TanakaSoft Materials Chemistry, Institute for Materials Chemistry and Engineering, Kyushu University, Fukuoka, Japan.
Rumi SawadaDivision of Cell-Based Therapeutic Products, National Institute of Health Sciences, Tokyo, Japan.
Shingo NiimiDivision of Medical Devices, National Institute of Health Sciences, Tokyo, Japan.
National Institute of Health Sciences · JPKyushu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Functionalizing biomaterials with peptides or polymers that enhance recruitment of endothelial cells (ECs) can reduce blood coagulation and thrombosis. To assess endothelialization of materials in vitro, primary ECs are generally used, although the characteristics of these cells vary among the donors and change with time in culture. Recently, primary cell lines immortalized by transduction of simian vacuolating virus 40 large T antigen or human telomerase reverse transcriptase have been developed. To determine whether immortalized ECs can substitute for primary ECs in material testing, we investigated endothelialization on biocompatible polymers using three lots of primary human umbilical vein endothelial cells (HUVEC) and immortalized microvascular ECs, TIME-GFP. Attachment to and growth on polymer surfaces were comparable between cell types, but results were more consistent with TIME-GFP. Our findings indicate that TIME-GFP is more suitable for in vitro endothelialization testing of biomaterials.

Indexed as

Biocompatible MaterialsMaterials TestingCell AdhesionCell Line, TransformedEndothelial CellsEndothelium, VascularHumansHuman Umbilical Vein Endothelial CellsPeptidesPolymersSurface PropertiesBiocompatible MaterialsPeptidesPolymers

Identifiers

PMID27348615
PMCPMC4922589
OpenAlexW2472063437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.